Associated tags: FDA, GRB2, Acute myeloid leukemia, Bone marrow, IND, RNA interference, STAT3, Lymphoma, Holding, Pharmaceutical industry, Patient, AML
Locations: GA, BELLAIRE, TX, US, UNITED STATES
In April, Bio-Path presented a poster highlighting preclinical BP1002 data at the 2021 American Association for Cancer Research (AACR) Annual Meeting.
Key Points:
- In April, Bio-Path presented a poster highlighting preclinical BP1002 data at the 2021 American Association for Cancer Research (AACR) Annual Meeting.
- Net cash provided by financing activities for the three months ended March 31, 2021 was $18.6 million.\nBio-Path Holdings will host a conference call and webcast today at 8:30 a.m.
- ET to review these first quarter 2021 financial results and to provide a general update on the Company.
- These documents are available on request from Bio-Path Holdings or at www.sec.gov .
ET to report financial results for the first quarter ended March 31, 2021 and to provide a business overview.\nTo access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5064037.
Key Points:
- ET to report financial results for the first quarter ended March 31, 2021 and to provide a business overview.\nTo access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5064037.
- A live audio webcast of the call will also be available on the Presentations section of the Company\xe2\x80\x99s website, www.biopathholdings.com .
- This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.
- For more information, please visit the Company's website at http://www.biopathholdings.com .\n"
This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.
Key Points:
- This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.
- These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances.
- Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
- Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n"
Chemical compounds,
Organic compounds,
Heterocyclic compounds,
Orphan drugs,
Otsuka Pharmaceutical,
Lactams,
Nucleosides,
Antineoplastic drugs,
Decitabine,
Venetoclax,
Decitabine/cedazuridine The safety run-in of Stage 2 of the Phase 2 clinical trial was comprised of six evaluable patients who were treated with the triple combination of prexigebersen, decitabine and venetoclax.
Key Points:
- The safety run-in of Stage 2 of the Phase 2 clinical trial was comprised of six evaluable patients who were treated with the triple combination of prexigebersen, decitabine and venetoclax.
- In the safety run-in, six evaluable patients were treated with the combination of prexigebersen, decitabine and venetoclax.
- CR rates to combination treatment with decitabine and venetoclax for relapsed/refractory AML patients is 42-52%1,2 and 0-39%1,2 for relapsed/refractory secondary AML patients.
- Finally, the third cohort treats relapsed/refractory AML patients who are venetoclax resistant or intolerant with the two-drug combination of prexigebersen and decitabine.
HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2021American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15 and May 17-21, 2021.
Key Points:
- HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2021American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15 and May 17-21, 2021.
- Dr. Maria Gagliardi, a Research Scientist at Bio-Path Holdings, will discuss pre-clinical studies of BP1002 (liposomal Bcl-2 antisense) in combination with decitabine as a potential treatment against venetoclax-resistant cells.
- Details for the virtual poster presentation are as follows:
Bio-Path is a biotechnology company developing DNAbilize, a novel technology that hasyielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion.
- This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in a Phase 1 study in advanced lymphoma and chronic lymphocytic leukemia patients.
Retrieved on:
Wednesday, March 10, 2021
As of December 31, 2020, the Company had cash of $13.8 million, compared to $20.4 million at December 31, 2019.
Key Points:
- As of December 31, 2020, the Company had cash of $13.8 million, compared to $20.4 million at December 31, 2019.
- Net cash provided by financing activities for the year ended December 31, 2020 was $4.3 million.
- ET to review these full-year 2020 financial results and to provide a general update on the Company.
- These documents are available on request from Bio-Path Holdings or at www.sec.gov .
ET to report financial results for the year ended December 31, 2020 and to provide a business overview.
Key Points:
- ET to report financial results for the year ended December 31, 2020 and to provide a business overview.
- A live audio webcast of the call will also be available on the Presentations section of the Companys website, www.biopathholdings.com .
- An archived webcast will be available on the Bio-Path website approximately two hours after the event.
- This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.
Retrieved on:
Thursday, February 18, 2021
Finance,
Stock market,
Financial economics,
U.S. Securities and Exchange Commission,
Initial public offering,
Financial markets,
Prospectus,
Registration statement,
Shelf registration,
Security,
SEC filings,
Red herring prospectus Roth Capital Partners acted as the sole placement agent for the offering.
Key Points:
- Roth Capital Partners acted as the sole placement agent for the offering.
- Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
- The securities described above were offered and sold by Bio-Path pursuant to a shelf registration statement on Form S-3 (Registration No.
- The offering of the securities was made only by means of a prospectus supplement that forms a part of the registration statement.
Retrieved on:
Tuesday, February 16, 2021
Financial economics,
Finance,
Financial markets,
Corporate finance,
Initial public offering,
Stock market,
Equity securities,
Prospectus,
Stock,
Public offering,
Red herring prospectus,
Regulation S-K The offering is expected to close on or about February 18, 2021, subject to customary closing conditions.
Key Points:
- The offering is expected to close on or about February 18, 2021, subject to customary closing conditions.
- Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
- 333-231537) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and was declared effective on June 5, 2019.
- A prospectus supplement relating to the shares of common stock will be filed with the SEC.
Retrieved on:
Saturday, February 13, 2021
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Key Points:
- The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Roth Capital Partners is acting as the sole placement agent for the offering.
- Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
- 333-231537) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and was declared effective on June 5, 2019.
